PH West Utah Pulmonary Hypertension Symposium

This live accredited activity is the only Mountain West symposium that focuses on the changing epidemiology of pulmonary vascular disease, discusses the role of genetics and epigenetics of various forms of Pulmonary Hypertension, and provides context and guidance for how to incorporate evolving treatment pathways.

This education is provided by leading physicians, researchers, and guideline authors in the field of pulmonary hypertension through a combination of didactic lectures, debates, and lively panel discussions.

Utah is well suited to host this conference with a long established history of pioneering genetic studies and outcomes research, and is at the forefront for the management of the methamphetamine epidemic.

Objectives

After completing this activity, the participant should be better able to:

• Evaluate innovative models of care and emerging technologies–including exercise interventions, digital health, and artificial intelligence–for their potential to enhance diagnosis, risk stratification, and treatment selection in pulmonary hypertension
• Discuss the use of combination therapies, transition treatment strategies, and add-on treatments in the management of PAH
• Analyze the evolving clinical research landscape in PAH, with emphasis on novel molecular pathways and investigational therapies in the pipeline
• Identify the unmet medical needs and unique clinical challenges of methamphetamine-associated pulmonary arterial hypertension (MA-PAH) and describe strategies for improving care and outcomes in this population
• Integrate new evidence and expert perspectives into management of pulmonary hypertension across clinical groups, including considerations for ILD-PH, Group 2 PH, and the ongoing debate surrounding treatment paradigms and disease classification

Target Audience

This activity is intended for physicians (pulmonologists, cardiologists, rheumatologists and general practitioners), fellows, residents, nurse practitioners, registered nurses and other healthcare practitioners engaged in the care of patients with pulmonary arterial hypertension.